Kodiak Sciences Inc.
KODHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Kodiak Sciences Inc. (KOD) is listed under Biotechnology. With a market capitalization of $2.67B, it sits in mid-cap territory. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Market Cap
$2.67B
Beta
2.20
P/E (TTM)
—
P/E (Fwd)
-13.68
EPS (TTM)
$-4.17
EPS (Fwd)
$-3.12
ROE
-208.8%
ROA
-49.1%
Cash
$169.5M
Total Debt
$56.0M
Free CF
-$52.2M
52W Change
672.5%
Annual Financials
Cash vs Debt
With $169.5M in cash and $56.0M in debt, KOD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$52.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -208.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, KOD tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kodiak Sciences Inc.'s trajectory.